These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24456101)

  • 1. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
    Adam V; Wauters I; Vansteenkiste J
    Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAGE A3 antigen-specific cancer immunotherapeutic.
    Peled N; Oton AB; Hirsch FR; Bunn P
    Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
    Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
    J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
    Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
    J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
    Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular biology of lung cancer series].
    Hiret S; Senellart H; Bennouna J
    Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
    McQuade JL; Homsi J; Torres-Cabala CA; Bassett R; Popuri RM; James ML; Vence LM; Hwu WJ
    BMC Cancer; 2018 Dec; 18(1):1274. PubMed ID: 30567529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to anticancer immunotherapy using gene signatures.
    Wang E; Bedognetti D; Marincola FM
    J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
    Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Chianese-Bullock KA; Mauldin IS; Smith KT; Deacon DH; Varhegyi NE; Donnelly SB; Reed CM; Scott K; Galeassi NV; Grosh WW
    Cancer Immunol Immunother; 2016 Jan; 65(1):25-36. PubMed ID: 26581199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.
    Sienel W; Varwerk C; Linder A; Kaiser D; Teschner M; Delire M; Stamatis G; Passlick B
    Eur J Cardiothorac Surg; 2004 Jan; 25(1):131-4. PubMed ID: 14690745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination therapy for non-small-cell lung cancer.
    Cuppens K; Vansteenkiste J
    Curr Opin Oncol; 2014 Mar; 26(2):165-70. PubMed ID: 24441502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
    Tyagi P; Mirakhur B
    Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
    Pujol JL; Vansteenkiste JF; De Pas TM; Atanackovic D; Reck M; Thomeer M; Douillard JY; Fasola G; Potter V; Taylor P; Bosquée L; Scheubel R; Jarnjak S; Debois M; de Sousa Alves P; Louahed J; Brichard VG; Lehmann FF
    J Thorac Oncol; 2015 Oct; 10(10):1458-67. PubMed ID: 26309191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
    Zandberg DP; Rollins S; Goloubeva O; Morales RE; Tan M; Taylor R; Wolf JS; Schumaker LM; Cullen KJ; Zimrin A; Ord R; Lubek JE; Suntharalingam M; Papadimitriou JC; Mann D; Strome SE; Edelman MJ
    Cancer Immunol Immunother; 2015 Mar; 64(3):367-79. PubMed ID: 25537079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
    Atanackovic D; Altorki NK; Cao Y; Ritter E; Ferrara CA; Ritter G; Hoffman EW; Bokemeyer C; Old LJ; Gnjatic S
    Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1650-5. PubMed ID: 18216244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
    Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
    Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.